**Table S1. Associations of Protease Inhibitors with Metabolic Health**

|  |
| --- |
| **S1a. Adjusted\* Per Year Prevalence Ratio (PR) for Metabolic Health Among PI Users** |
|  | Participants exposed (n) | Median (IQR) exposure (years) | PR (95%Confidence Interval)  | P value |
| Saquinavir | 199 | 2.0 (0.6, 4.5) | 1.00 (0.97, 1.03) | 0.94 |
| Ritonavir (any dose) | 563 | 6.4 (2.3, 9.8) | 0.99 (0.98, 1.00) | 0.17 |
| Indinavir | 286 | 2.9 (1.1, 5.5) | 0.99 (0.97, 1.01) | 0.33 |
| Nelfinavir | 263 | 2.0 (0.6, 4.2) | 0.99 (0.96, 1.01) | 0.35 |
| Amprenavir | 64 | 1.9 (0.7, 3.3) | 0.91 (0.82, 1.01) | 0.08 |
| Lopinavir | 237 | 4.0 (1.1, 7.1) | 0.99 (0.98, 1.01) | 0.57 |
| Atazanavir | 273 | 5.0 (1.8, 7.8) | 0.99 (0.98, 1.01) | 0.47 |
| Fosamprenavir | 62 | 4.1 (1.8, 6.5) | 0.99 (0.95, 1.03) | 0.57 |
| Tipranavir | 16 | 0.5 (0.4, 1.8) | 1.01 (0.89, 1.16) | 0.83 |
| Darunavir | 219 | 2.2 (1.0, 4.3) | 0.95 (0.91, 0.99) | 0.01 |
| **S1b. Adjusted\*\* Per Year PR for Metabolic Health Among PI Users** |
|  | Participants exposed (n) | Median (IQR) exposure (years) | PR (95% Confidence Interval)  | P value |
| Saquinavir | 199 | 2.0 (0.6, 4.5) | 1.01 (0.98, 1.04) | 0.62 |
| Indinavir | 286 | 2.9 (1.1, 5.5) | 1.00 (0.98, 1.03) | 0.74 |
| Nelfinavir | 263 | 2.0 (0.6, 4.2) | 0.99 (0.97, 1.01) | 0.43 |
| Amprenavir | 64 | 1.9 (0.7, 3.3) | 0.92 (0.83, 1.02) | 0.13 |
| Lopinavir | 237 | 4.0 (1.1, 7.1) | 1.00 (0.98, 1.03) | 0.70 |
| Atazanavir | 273 | 5.0 (1.8, 7.8) | 0.99 (0.98, 1.01) | 0.37 |
| Fosamprenavir | 62 | 4.1 (1.8, 6.5) | 1.00 (0.96, 1.04) | 0.95 |
| Tipranavir | 16 | 0.5 (0.4, 1.8) | 1.01 (0.90, 1.13) | 0.82 |
| Darunavir | 219 | 2.2 (1.0, 4.3) | 0.95 (0.91, 0.99) | 0.01 |

\*Adjusted for BMI, age, race, smoking, HCV RNA+, CD4+ T lymphocyte count <500 cells/μL

\*\*Adjusted for BMI, age, race, smoking, HCV RNA+, CD4+ T lymphocyte count <500 cells/μL, per year zidovudine, stavudine and ritonavir use

PR=prevalence ratio, PI=protease inhibitor, IQR=interquartile range